Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1976 Sep;58(3):742–750. doi: 10.1172/JCI108521

Heterogeneity of plasma glucagon. Circulating components in normal subjects and patients with chronic renal failure.

S F Kuku, J B Jaspan, D S Emmanouel, A Zeidler, A I Katz, A H Rubenstein
PMCID: PMC333233  PMID: 956399

Abstract

Plasma immunoreactive glucagon (IRG) concentrations were measured in 36 patients with chronic renal failure (CRF) and 32 normal subjects. In addition, the components of circulating IRG were analyzed by gel filtration in the fasting state and after physiological stimuli. Fasting IRG was elevated (P less than 0.001) in CRF patients (534 +/- 32 pg/ml) compared with the levels found in healthy subjects (113 +/- 9 pg/ml). Oral glucose suppressed plasma IRG in CRF patients from a basal level of 568 +/- 52 to a nadir of 354 +/- 57 pg/ml (120 min). This degree of suppression (38%) was comparable to that found in normal subjects (basal = 154 +/- 20 to 100 +/- 23 pg/ml) at 120 min (35%). Intravenous infusion of arginine (250 mg/kg) resulted in a 71% rise in IRG in CRF patients and a 166% increase in normal subjects. Gel filtration of fasting plasma from CRF patients showed three major peaks. The earliest (A) was found in the void volume (mol wt greater than 40,000) and constituted 16.5 +/- 4.7% of the elution profile. The middle peak (B) eluted just beyond the proinsulin marker (approximately 9,000 mol wt) and constituted the largest proportion of the elution profile (56.5 +/- 3.4%). The third peak (C) coincided with the standard glucagon and [125I]glucagon markers (3,485 mol wt) and comprised 27.0 +/- 4% of the IRG profile. In contrast, only peaks A and C were found in fasting plasma of normal subjects (53.6 +/- 10.4% in A and 46.4 +/- 10.4 in C). After oral glucose, glucagon immunoreactivity in the 3,500 mol wt peak (C) was markedly suppressed, while the B peak in patients with CRF declined to a lesser extent. The A peak in both groups was unchanged. After an arginine infusion only the C peak increased in both groups of subjects. Gel filtration of plasma in 3 M acetic acid gave similar profiles to those obtained in glycine albumin buffer. Exposure of serum to trypsin indicated that the B and C peaks were digestible, while the A peak was resistant to the action of the enzyme. In one sample, peak C increased after a 2-h exposure of serum to trypsin. We conclude that circulating IRG in normal subjects and patients with CRF is heterogenous. The hyperglucagonemia of renal failure is largely due to an increase in IRG material of approximately 9,000 mol wt, consistent with proglucagon, although the 3,500 mol wt component is also considerably elevated (threefold). The significance of circulating IRG levels should be interpreted with caution until the relative biological activity of the three components is established.

Full text

PDF
742

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bilbrey G. L., Faloona G. R., White M. G., Atkins C., Hull A. R., Knochel J. P. Hyperglucagonemia in uremia: reversal by renal transplantation. Ann Intern Med. 1975 Apr;82(4):525–528. doi: 10.7326/0003-4819-82-4-525. [DOI] [PubMed] [Google Scholar]
  2. Bilbrey G. L., Faloona G. R., White M. G., Knochel J. P. Hyperglucagonemia of renal failure. J Clin Invest. 1974 Mar;53(3):841–847. doi: 10.1172/JCI107624. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Hellerström C., Howell S. L., Edwards J. C., Andersson A., Ostenson C. G. Biosynthesis of glucagon in isolated pancreatic islets of guinea pigs. Biochem J. 1974 Apr;140(1):13–21. doi: 10.1042/bj1400013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Kuku S. F., Zeidler A., Emmanouel D. S., Katz A. I., Rubenstein A. H. Heterogeneity of plasma glucagon: patterns in patients with chronic renal failure and diabetes. J Clin Endocrinol Metab. 1976 Jan;42(1):173–176. doi: 10.1210/jcem-42-1-173. [DOI] [PubMed] [Google Scholar]
  5. Lefebvre P. J., Luyckx A. S. Effect of acute kidney exclusion by ligation of renal arteries on peripheral plasma glucagon levels and pancreatic glucagon production in the anesthetized dog. Metabolism. 1975 Oct;24(10):1169–1176. doi: 10.1016/0026-0495(75)90153-5. [DOI] [PubMed] [Google Scholar]
  6. Mashiter K., Harding P. E., Chou M., Mashiter G. D., Stout J., Diamond D., Field J. B. Persistent pancreatic glucagon but not insulin response to arginine in pancreatectomized dogs. Endocrinology. 1975 Mar;96(3):678–693. doi: 10.1210/endo-96-3-678. [DOI] [PubMed] [Google Scholar]
  7. Noe B. D., Bauer G. E. Evidence for glucagon biosynthesis involving a protein intermediate in islets of the anglerfish (Lophius americanus). Endocrinology. 1971 Sep;89(3):642–651. doi: 10.1210/endo-89-3-642. [DOI] [PubMed] [Google Scholar]
  8. Noe B. D., Bauer G. E. Evidence of sequential metabolic cleavage of proglucagon to glucagon in glucagon biosynthesis. Endocrinology. 1975 Oct;97(4):868–877. doi: 10.1210/endo-97-4-868. [DOI] [PubMed] [Google Scholar]
  9. Noe B. D., Bauer G. E., Steffes M. W., Sutherland D. E., Najarian J. S. Glucagon biosynthesis in human pancreatic islets: preliminary evidence for a biosynthetic intermediate. Horm Metab Res. 1975 Jul;7(4):314–322. doi: 10.1055/s-0028-1093721. [DOI] [PubMed] [Google Scholar]
  10. Rigopoulou D., Valverde I., Marco J., Faloona G., Unger R. H. Large glucagon immunoreactivity in extracts of pancreas. J Biol Chem. 1970 Feb 10;245(3):496–501. [PubMed] [Google Scholar]
  11. Tager H. S., Steiner D. F. Isolation of a glucagon-containing peptide: primary structure of a possible fragment of proglucagon. Proc Natl Acad Sci U S A. 1973 Aug;70(8):2321–2325. doi: 10.1073/pnas.70.8.2321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Trakatellis A. C., Tada K., Yamaji K., Gardiki-Kouidou P. Isolation and partial characterization of anglefish proglucagon. Biochemistry. 1975 Apr 8;14(7):1508–1512. doi: 10.1021/bi00678a025. [DOI] [PubMed] [Google Scholar]
  13. Valverde I., Dobbs R., Unger R. H. Heterogeneity of plasma glucagon immunoreactivity in normal, depancreatized, and alloxan-diabetic dogs. Metabolism. 1975 Sep;24(9):1021–1028. doi: 10.1016/0026-0495(75)90095-5. [DOI] [PubMed] [Google Scholar]
  14. Valverde I., Villanueva M. L., Lozano I., Marco J. Presence of glucagon immunoreactivity in the globulin fraction of human plasma ("big plasma glucagon"). J Clin Endocrinol Metab. 1974 Dec;39(6):1090–1098. doi: 10.1210/jcem-39-6-1090. [DOI] [PubMed] [Google Scholar]
  15. Weir G. C., Knowlton S. D., Martin D. B. High molecular weight glucagon-like immunoreactivity in plasma. J Clin Endocrinol Metab. 1975 Feb;40(2):296–302. doi: 10.1210/jcem-40-2-296. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES